US4968792A - Psychotropic benzisothiazole derivatives - Google Patents

Psychotropic benzisothiazole derivatives Download PDF

Info

Publication number
US4968792A
US4968792A US07/412,256 US41225689A US4968792A US 4968792 A US4968792 A US 4968792A US 41225689 A US41225689 A US 41225689A US 4968792 A US4968792 A US 4968792A
Authority
US
United States
Prior art keywords
benzisothiazol
dione
pharmaceutically acceptable
piperazinyl
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/412,256
Inventor
Gary P. Stack
Magid A. Abou-Gharbia
Thomas D. Golobish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Priority to US07/412,256 priority Critical patent/US4968792A/en
Assigned to AMERICAN HOME PRODUCTS CORPORATION reassignment AMERICAN HOME PRODUCTS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: GOLOBISH, THOMAS D., ABOU-GHARBIA, MAGID ABDEL-MEGID, STACK, GARY P.
Application granted granted Critical
Publication of US4968792A publication Critical patent/US4968792A/en
Assigned to WYETH reassignment WYETH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: AMERICAN HOME PRODUCTS CORPORATION
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • U.S. Pat. No. 4,411,901 and related divisional U.S. Pat. No. 4,452,799 disclose a series of benzisothiazole and benzisoxazole piperazine derivatives having selective antipsychotic activity.
  • U.S. Pat. No. 4,656,173 discloses the antipsychotic activity of a benzisothiazole S-oxide derivative.
  • U.S. Pat. No. 4,797,488 discloses N-(aryl and heteroarylpiperazinylalkyl)polycyclic-1,3-dicarboxylic acid imides useful as antipsychotic and/or anxiolytic agents.
  • U.S. Pat. No. 4,732,983 discloses antipsychotic and/or anxiolytic N-(aryl and heteroarylpiperazinylalkyl)polycyclic dicarboxylic acid imides.
  • a group of antipsychotic/anxiolytic agents of the formula: ##STR1## wherein R 1 is hydrogen, hydroxy, cyano, alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms, halo or trifluoromethyl; (O) represents optional oxidation of sulfur; n is 2 to 5 and Z is ##STR2## wherein X is alkylene of 1 to 4 carbon atoms or alkylidene of 2 to 4 carbon atoms; Q is alkylene of 1 to 4 carbon atoms, alkylidene of 2 to 4 carbon atoms, or ##STR3## or a pharmaceutically acceptable salt thereof.
  • R 1 is hydrogen, hydroxy, methoxy, bromo or chloro; n is 4; Z is (II) wherein X is ethenylene and Q is methylene or ethenylene; or Z is (III) wherein X is methylene and Q is ##STR4## or Z is (IV) or (V) or a pharmaceutically acceptable said thereof.
  • Still further preferred compounds are designated:
  • the pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, maleic, malonic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known pharmaceutically acceptable acids.
  • the compounds of this invention are prepared by conventional methods. For example, a polycyclic 1,2- or 1,3-dicarboxylic acid or anhydride derived therefrom is refluxed with the desired benzisothiazolyl piperazinyl alkylamine in dry pyridine, toluene or xylene. Water removal may be achieved by either chemical (e.g. ethoxyacetylene) or mechanical (e.g. Dean-Stark trap) means.
  • chemical e.g. ethoxyacetylene
  • mechanical e.g. Dean-Stark trap
  • polycyclic dicarboxylic acids themselves are known compounds or they can be prepared from the appropriate polycyclic olefin by treatment with a suitable oxidizing agent such as potassium permanganate or ruthenium tetroxide (or from the appropriate polycyclic ketone by treatment with potassium permanganate or potassium trioxide or from the appropriate diketone via treatment with periodic acid).
  • a suitable oxidizing agent such as potassium permanganate or ruthenium tetroxide
  • the compounds of this invention are readily prepared from the analogous polycyclic imide via alkylation with a suitable dihalo-lower-alkane in the presence of a strong base such as sodium hydride followed by reaction of the intermediate product with the desired benzisothiazolyl piperazine, thusly: ##STR6## wherein n and R 1 are as defined above.
  • the compounds of this invention possess high affinities for the dopamine D-2 receptor and the serotonin 5-HT 1A receptor, and consequently, they are useful as antipsychotic and anxiolytic agents for the treatment of a variety of central nervous system disorders such as schizophrenia, anxiety, sleep disorders, and related problems.
  • the antipsychotic properties of the compound of Example 5 were further established by standard pharmacologically accepted procedures involving conditioned avoidance studies in which trained male CD rats (Charles River), 400-500 g. body weight are exposed to a fifteen second warning tone (conditioned stimulus) continued for an additional fifteen seconds accompanied by electric shock.
  • the rat can avoid the electric shock by jumping to an exposed shelf (shelf-jump response).
  • a response during the initial warning tone is considered an avoidance response, while a response during shock delivery is considered an escape response.
  • the shelf-jump response test procedure follows that of Herman et. al., Comm. in Psychopharm., 3, pp. 165-171 (1979).
  • the compounds of this invention are useful in the treatment of various CNS disorders amenable to treatment with antipsychotic and anxiolytic agents. They may be administered neat or with a pharmaceutical carrier to a patient in need thereof by the attending physician.
  • the pharmaceutical carrier may be a solid or liquid.
  • Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material.
  • the carrier is a finely divided solid which is in admixture with the finely divided active ingredient.
  • the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain up to 99% of the active ingredient.
  • Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
  • Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs.
  • the active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat.
  • the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators.
  • suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above e.g.
  • cellulose derivatives preferably sodium carboxymethyl cellulose solution
  • alcohols including monohydric alcohols and polyhydric alcohols e.g. glycols
  • oils e.g. fractionated coconut oil and arachis oil
  • the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate.
  • Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either in liquid or solid composition form.
  • the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules.
  • the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient;
  • the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids.
  • the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
  • the dosage to be used in the treatment of a specific psychosis must be subjectively determined by the attending physician.
  • the variables involved include the specific psychosis or state of anxiety and the size, age and response pattern of the patient.
  • Example 2 The compound prepared in Example 1 (13.00 g, 28.2 mmol) was converted to the freebase by washing a methylene chloride solution of the compound with saturated aqueous sodium bicarbonate. After drying over Na 2 SO 4 , filtration, and evaporation in vacuo, the residue was dissolved in 400 mL of methanol. To this solution was added 4 mL of hydrazine (124 mmol) and the reaction was refluxed overnight. The resulting solution was evaporated in vacuo. The residue was redissolved in methylene chloride and washed with aqueous sodium carbonate. The aqueous layer was re-extracted with 2 additional portions of methylene chloride.
  • the product was column chromatographed by HPLC on silica with a gradient elution beginning with 10% hexane/ethyl acetate, then ethyl acetate, and finally 5% methanol/ethyl acetate.
  • the product-containing fractions were combined and evaporated to yield 2.22 g of product.
  • the residue was crystallized from isopropanol with the addition of 4N HCl in isopropanol to yield 2.03 g of the title compound as the dihydrochloride, m.p. 233°-235° C.
  • the product was column chromatographed by HPLC on silica with a gradient elution beginning with 10% hexane/ethyl acetate, then ethyl acetate, and finally 5% MeOH/ethyl acetate.
  • the product-containing fractions were combined and evaporated to yield 4.35 g of product.
  • the residue was crystallized from isopropanol with the addition of 4N HCl in isopropanol to yield 4.05 g of the title compound as the hydrochloride three quarter hydrate, m.p. 264°-266° C.
  • the product was column chromatographed by HPLC on silica with a gradient elution beginning with methylene chloride and ending with 2% methanol in methylene chloride. The product-containing fractions were combined and evaporated to yield 1.40 g of product. The residue was crystallized from isopropanol with the addition of 4N HCl in isopropanol to yield 440 mg of the title compound as the hydrochloride hemihydrate, m.p. 215°-217° C.
  • Example 6 The endo isomer from Example 6 was crystallized from isopropanol with the addition of 4N HCl isopropanol to yield 4.82 g of the title compound as the hydrochloride quarter hydrate, m.p. 263°-264° C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein are novel benzisothiazole derivatives having pharmacological activity, to a process for preparing them, to pharmaceutical compositions containing them, and to their use in the treatment of a variety of central nervous system disorders.

Description

BACKGROUND OF THE INVENTION
U.S. Pat. No. 4,411,901 and related divisional U.S. Pat. No. 4,452,799 disclose a series of benzisothiazole and benzisoxazole piperazine derivatives having selective antipsychotic activity.
U.S. Pat. No. 4,656,173 discloses the antipsychotic activity of a benzisothiazole S-oxide derivative.
Great Britain Patent No. 2,181,731-A discloses fused N-substituted bicyclic imides useful as antipsychotic and/or anxiolytic agents.
U.S. Pat. No. 4,797,488 discloses N-(aryl and heteroarylpiperazinylalkyl)polycyclic-1,3-dicarboxylic acid imides useful as antipsychotic and/or anxiolytic agents.
U.S. Pat. No. 4,732,983 discloses antipsychotic and/or anxiolytic N-(aryl and heteroarylpiperazinylalkyl)polycyclic dicarboxylic acid imides.
DESCRIPTION OF THE INVENTION
In accordance with this invention, there is provided a group of antipsychotic/anxiolytic agents of the formula: ##STR1## wherein R1 is hydrogen, hydroxy, cyano, alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms, halo or trifluoromethyl; (O) represents optional oxidation of sulfur; n is 2 to 5 and Z is ##STR2## wherein X is alkylene of 1 to 4 carbon atoms or alkylidene of 2 to 4 carbon atoms; Q is alkylene of 1 to 4 carbon atoms, alkylidene of 2 to 4 carbon atoms, or ##STR3## or a pharmaceutically acceptable salt thereof.
Of these compounds of formula (I), the preferred members are those in which R1 is hydrogen, hydroxy, methoxy, bromo or chloro; n is 4; Z is (II) wherein X is ethenylene and Q is methylene or ethenylene; or Z is (III) wherein X is methylene and Q is ##STR4## or Z is (IV) or (V) or a pharmaceutically acceptable said thereof.
Still further preferred compounds are designated:
decahydro-3-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,5-methano-6,7,9-metheno-2H-pentaleno[1,2-d]azepine-2,4(3H)-dione;
2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-3a,4,4a,6a,7,7a-hexahydro-4,7-etheno-1H-cyclobut[f]isoindole-1,3(2H)-dione;
2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-4,4a,5,5a,6,6a-hexahydro-4,6-ethenocycloprop[f]isoindole-1,3(2H,3aH)-dione;
2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1H-isoindole-1,3(2H)-dione;
(exo)-octahydro-2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-4,5,7-metheno-1H-pentaleno[1,2-c]pyrrole-1,3(1H)-dione;
(endo)-octahydro-2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-4,5,7-metheno-1H-pentaleno[1,2-c]pyrrole-1,3(2H)-dione;
and the pharmaceutically acceptable salts thereof.
The pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, maleic, malonic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known pharmaceutically acceptable acids.
The compounds of this invention are prepared by conventional methods. For example, a polycyclic 1,2- or 1,3-dicarboxylic acid or anhydride derived therefrom is refluxed with the desired benzisothiazolyl piperazinyl alkylamine in dry pyridine, toluene or xylene. Water removal may be achieved by either chemical (e.g. ethoxyacetylene) or mechanical (e.g. Dean-Stark trap) means.
The polycyclic dicarboxylic acids themselves are known compounds or they can be prepared from the appropriate polycyclic olefin by treatment with a suitable oxidizing agent such as potassium permanganate or ruthenium tetroxide (or from the appropriate polycyclic ketone by treatment with potassium permanganate or potassium trioxide or from the appropriate diketone via treatment with periodic acid). These procedures may be illustrated as follows: ##STR5##
Alternatively, the compounds of this invention are readily prepared from the analogous polycyclic imide via alkylation with a suitable dihalo-lower-alkane in the presence of a strong base such as sodium hydride followed by reaction of the intermediate product with the desired benzisothiazolyl piperazine, thusly: ##STR6## wherein n and R1 are as defined above.
Compounds of formula (I) which bear the optional oxidation state of sulfur may be conveniently prepared from the corresponding divalent sulfur-containing compounds. While various oxidative preparatory methods may be employed, it was found most convenient to effect the oxidation at low temperatures with mixed sulfuric and nitric acids.
The compounds of this invention possess high affinities for the dopamine D-2 receptor and the serotonin 5-HT1A receptor, and consequently, they are useful as antipsychotic and anxiolytic agents for the treatment of a variety of central nervous system disorders such as schizophrenia, anxiety, sleep disorders, and related problems.
High affinity for the dopamine D-2 receptor was established by the standard experimental test procedure of Fields, et al., Brain Res., 136, 578-584 (1977) and Yamamura et al., eds., Neurotransmitter Receptor Binding, Raven Press, N.Y. (1978) wherein homogenized limbic brain tissue is incubated with 3 H-spiroperiodol and various concentrations of test compound, filtered and washed and shaken with Hydrofluor scintillation cocktail (National Diagnostics) and counted in a Packard 460 CD scintillation counter. The results of this testing with compounds representative of this invention are given below.
High affinity for the serotonin 5-HT1A receptor was established by testing the claimed compound's ability to displace [3 H]8-OHDPAT (dipropylaminotetralin) from the 5-HT1A serotonin receptor following the procedure of Hall et al., J. Neurochem. 44, 1685 (1985). This procedure is employed to analogize this property of the claimed compounds with that of buspirone, which is a standard for anxiolytic activity, and, like the compounds of this invention, displays high affinity for the 5-HT1A serotonin receptor subtype. The anxiolytic activity of buspirone is believed to be, at least partially, due to its 5-HT1A receptor affinity (Vander Maelen et al., Eur. J. Pharmacol., 129 (1-2) 123-130 (1986).
The results of the two standard experimental test procedures described in the preceding two paragraphs were as follows:
______________________________________                                    
        D-2 Binding  5-HT.sub.1A Binding                                  
          (Inhibition        (Inhibition                                  
Compound  at 1 μM)                                                     
                    (K.sub.i, nM)                                         
                             at 1 μM)                                  
                                     (K.sub.i, nM)                        
______________________________________                                    
Example 3 99%                100%    --                                   
Example 4 95%                 97%    0.65                                 
Example 5 95%       0.50      96%    0.065                                
Example 6 100%               100%    --                                   
Example 7 100%               100%    0.4                                  
______________________________________
The antipsychotic properties of the compound of Example 5 were further established by standard pharmacologically accepted procedures involving conditioned avoidance studies in which trained male CD rats (Charles River), 400-500 g. body weight are exposed to a fifteen second warning tone (conditioned stimulus) continued for an additional fifteen seconds accompanied by electric shock. The rat can avoid the electric shock by jumping to an exposed shelf (shelf-jump response). A response during the initial warning tone is considered an avoidance response, while a response during shock delivery is considered an escape response. The shelf-jump response test procedure follows that of Herman et. al., Comm. in Psychopharm., 3, pp. 165-171 (1979). A similar test procedure (Discrete Trial) in which a lever press was substituted for a shelf-jump was also used to establish the activity of the compound of Example 5. The compound was tested over a full dose range and the Avoidance Block activities reported as "AB50 's (mg/kg): Shelf-jump: 6.43 (no CI) i.p., 58.28 (no CI) p.o.; Discrete Trial: 4.80 (2.14-17.66) i.p., 35.35 (no CI) p.o.
Hence, the compounds of this invention are useful in the treatment of various CNS disorders amenable to treatment with antipsychotic and anxiolytic agents. They may be administered neat or with a pharmaceutical carrier to a patient in need thereof by the attending physician. The pharmaceutical carrier may be a solid or liquid.
Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.
Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either in liquid or solid composition form.
Preferably, the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
The dosage to be used in the treatment of a specific psychosis must be subjectively determined by the attending physician. The variables involved include the specific psychosis or state of anxiety and the size, age and response pattern of the patient.
The following examples illustrate the production of representative compounds of this invention.
EXAMPLE 1 2-[4-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]butyl]-1H-isoindole-1,3(2H)-dione
An 18.01 g sample of 1-(1,2-benzisothiazol-3-yl)piperazine (83.7 mmol), 29.5 g of N-(4-bromobutyl)phthalimide (104.6 mmol) and 36 mL of N,N-diisopropylethylamine (375.4 mmol) were added to 400 mL of dry DMF. The solution was heated at 80° C. for 18 hours, and the solvent was then removed in vacuo. The residue was dissolved in 500 mL of methylene chloride and was washed with saturated aqueous sodium bicarbonate. The combined aqueous layers were re-extracted with 2 portions of methylene chloride. The combined organic layers were dried over Na2 SO4, filtered, and concentrated in vacuo. The residue was crystallized from isopropanol with the addition of 4N HCl/isopropanol to give 23.03 g of the title compound as the hydrochloride, quarter hydrate, m.p. 253°-255° C.
Anal. Calcd. for C23 H24 N4 O2 S.HCl.1/4H2 O: C, 59.85; H, 5.57; N, 12.14; Found: C, 59.84; H, 5.73; N, 12.14.
EXAMPLE 2 4-(1,2-Benzisothiazol-3-yl)-1-piperazinebutanamine
The compound prepared in Example 1 (13.00 g, 28.2 mmol) was converted to the freebase by washing a methylene chloride solution of the compound with saturated aqueous sodium bicarbonate. After drying over Na2 SO4, filtration, and evaporation in vacuo, the residue was dissolved in 400 mL of methanol. To this solution was added 4 mL of hydrazine (124 mmol) and the reaction was refluxed overnight. The resulting solution was evaporated in vacuo. The residue was redissolved in methylene chloride and washed with aqueous sodium carbonate. The aqueous layer was re-extracted with 2 additional portions of methylene chloride. The combined organic layers were dried with Na2 SO4, filtered and evaporated to yield 8.07 g of free base. A 1 g sample of free base was crystallized from isopropanol with the addition of 4N HCl in isopropanol to yield 500 mg of the title compound as the dihydrochloride hydrate, m.p. 262°-265° C.
Anal. Calcd. for C15 H22 N4 S.2HCl.H2 O: C, 47.24; H, 6.87; N, 14.69; Found: C, 47.62; H, 6.48; N, 14.88.
EXAMPLE 3 2-[4-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]butyl]-4,4a,5,5a,6,6a-hexahydro-4,6-ethenocycloprop[f]isoindole-1,3(2H,3aH)-dione
An 1.00 g (53 mmol) sample of hexahydro-4,6-ethenocycloprop[f]benzofuran-1,3(2H, 3aH)-dione and 1.64 g (5.3 mmol) of 4-(1,2-benzisothiazol-3-yl)-1-piperazinebutanamine were combined in 300 mL of xylenes. The mixture was refluxed under nitrogen overnight with water removal via a Dean-Stark trap. The solvent was then removed in vacuo to yield 2.99 g of residue. The product was column chromatographed by HPLC on silica with a gradient elution beginning with 10% hexane/ethyl acetate, then ethyl acetate, and finally 5% methanol/ethyl acetate. The product-containing fractions were combined and evaporated to yield 2.22 g of product. The residue was crystallized from isopropanol with the addition of 4N HCl in isopropanol to yield 2.03 g of the title compound as the dihydrochloride, m.p. 233°-235° C.
Anal. Calcd. for C26 H30 N4 O2 S.2HCl: C, 58.31; H, 6.02; N, 10.40; Found: C, 58.50; H, 5.90; N, 10.10.
EXAMPLE 4 2-[4-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]butyl]3a,4,4a,6a,7,7a-hexahydro-4,7-etheno-1H-cyclobut[f]isoindole-1,3(2H)-dione
An 2.02 g (10 mmol) sample of hexahydro-4,7-etheno-1H-cyclobut[f]isobenzofuran-1,3(2H)-dione and 3.10 g (10 mmol) of 4-(1,2-benzisothiazol-3-yl)-1-piperazineutanamine was combined in 300 mL of xylenes. The mixture was refluxed under nitrogen overnight with water removal via a Dean-Stark trap. The solvent was then removed in vacuo to yield 5.15 g of crude product. The product was column chromatographed by HPLC on silica with a gradient elution beginning with 10% hexane/ethyl acetate, then ethyl acetate, and finally 5% MeOH/ethyl acetate. The product-containing fractions were combined and evaporated to yield 4.35 g of product. The residue was crystallized from isopropanol with the addition of 4N HCl in isopropanol to yield 4.05 g of the title compound as the hydrochloride three quarter hydrate, m.p. 264°-266° C.
Anal. Calcd. for C27 H30 N4 O2 S.HCl.3/4H2 O: C, 61.81; H, 6.25; N, 10.68; Found: C, 61.82; H, 6.14; N, 10.50.
EXAMPLE 5 Decahydro-3-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,5-methano-6,7,9-metheno-2H-pentaleno[1,2-d]azepine-2,4(3H)-dione
An 2.3 g (10 mmol) of decahydro-1,5-methano-6,8,9-methenopentaleno-[1,2-d]oxepine-2,4-(1H,5H)-dione was added to 300 mL xylenes along with 3.28 g (10 mmol) of 4-(1,2-benzisothiazol-3-yl)-1-piperazinebutanamine. The mixture was refluxed under nitrogen overnight with water removal via a Dean-Stark trap. The solvent was then removed in vacuo to yield 5.49 g of crude material. The product was column chromatographed by HPLC on silica with a gradient elution beginning with methylene chloride and ending with 2% methanol in methylene chloride. The product-containing fractions were combined and evaporated to yield 1.40 g of product. The residue was crystallized from isopropanol with the addition of 4N HCl in isopropanol to yield 440 mg of the title compound as the hydrochloride hemihydrate, m.p. 215°-217° C.
Anal. Calcd. for C29 H34 N4 O2 S.HCl.1/2H2 O: C, 63.54; H, 6.62; N, 10.22; Found: C, 63.36; H, 6.49; N, 9.89.
EXAMPLE 6 (Exo)-octahydro-2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-4,5,7-metheno-1H-pentaleno[1,2-c]pyrrole-1,3(1H)-dione
Octahydro-4,5,7-methenopentaleno[1,2-c]furan-1,3-dione (3.28 g, 20 mmol) was combined with 6.17 g (20 mmol) of 4-(1,2-benzisothiazol-3-yl)-1-piperazinebutanamine in 300 mL of xylene and refluxed under nitrogen overnight with a Dean-Stark trap. The solvent was removed in vacuum to yield 10.59 g of crude product. The residue was column chromatographed by HPLC on silica with a gradient elution beginning with 20% isopropanol in hexane and ending with 50% isopropanol/hexane. The exo and endo isomers were separated to yield 1.97 g and 4.76 g respectively. The exo product was crystallized from isopropanol with the addition of 4N HCl isopropanol to yield 1.46 g of the title compound as the hydrochloride, m.p. 220°-221° C.
Anal. Calcd. for C26 H30 N4 O2 S.HCl: C, 62.57; H, 6.26; N, 11.23; Found: C, 62.43; H, 6.32; N, 11.19.
EXAMPLE 7 (Endo)-octahydro-2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-4,5,7-metheno-1H-pentaleno[1,2-c]pyrrole-1,3(2H)-dione
The endo isomer from Example 6 was crystallized from isopropanol with the addition of 4N HCl isopropanol to yield 4.82 g of the title compound as the hydrochloride quarter hydrate, m.p. 263°-264° C.
Anal. Calcd. for C26 H31 N4 O2 SCl.1/4H2 O: C, 62.01; H, 6.31; N, 11.13; Found: C, 62.01; H, 6.47; N, 10.95.

Claims (8)

We claim:
1. The compounds of formula (I) ##STR7## wherein R1 is hydrogen, hydroxy, cyano, alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms, halo or trifluoromethyl; (O) represents optional oxidation of sulfur; n is 2 to 5 and Z is ##STR8## wherein X is alkylene of 1 to 4 carbon atoms or alkylidene of 2 to 4 carbon atoms; Q is alkylene of 1 to 4 carbon atoms, alkylidene of 2 to 4 carbon atoms, or ##STR9## or a pharmaceutically acceptable salt thereof.
2. The compounds according to claim 1 wherein R1 is hydrogen, hydroxy, methoxy, bromo or chloro; n is 4; Z is (II) wherein X is ethenylene and Q is methylene or ethenylene; or Z is (III) wherein X is methylene and Q is ##STR10## or Z is (IV) or (V) or a pharmaceutically acceptable salt thereof.
3. A compound of claim 2 which is decahydro-3-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,5-methano-6,7,9-metheno-2H-pentaleno[1,2-d]azepine-2,4(3H)-dione or a pharmaceutically acceptable salt thereof.
4. A compound of claim 2 which is 2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-3a,4,4a,6a,7,7a-hexahydro-4,7-etheno-1H-cyclobut[f]isoindole-1,3(2H)-dione or a pharmaceutically acceptable salt thereof.
5. A compound of claim 2 which is 2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-4,4a,5,5a,6,6a-hexahydro-4,6-ethenocycloprop[f]isoindole-1,3(2H,3aH)-dione or a pharmaceutically acceptable salt thereof.
6. A compound of claim 2 which is 2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1H-isoindole-1,3(2H)-dione or a pharmaceutically acceptable salt thereof.
7. A compound of claim 2 which is (exo)-octahydro-2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-4,5,7-metheno-1H-pentaleno[1,2-c]pyrrole-1,3(1H)-dione or a pharmaceutically acceptable salt thereof.
8. A compound of claim 2 which is (endo)-octahydro-2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-4,5,7-metheno-1H-pentaleno[1,2-c]pyrrole-1,3(2H)-dione or a pharmaceutically acceptable salt thereof.
US07/412,256 1989-09-25 1989-09-25 Psychotropic benzisothiazole derivatives Expired - Lifetime US4968792A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/412,256 US4968792A (en) 1989-09-25 1989-09-25 Psychotropic benzisothiazole derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/412,256 US4968792A (en) 1989-09-25 1989-09-25 Psychotropic benzisothiazole derivatives

Publications (1)

Publication Number Publication Date
US4968792A true US4968792A (en) 1990-11-06

Family

ID=23632273

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/412,256 Expired - Lifetime US4968792A (en) 1989-09-25 1989-09-25 Psychotropic benzisothiazole derivatives

Country Status (1)

Country Link
US (1) US4968792A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016073A1 (en) * 1992-02-12 1993-08-19 The Wellcome Foundation Limited Piperazine and piperidine derivatives, and their use as antipsychotics
US5550130A (en) * 1989-05-19 1996-08-27 Hoechst-Roussel Pharmaceuticals, Inc. 1-[(1,4-benzodioxanyl)alkyl]-4-(heteroaryl)piperidines and related compounds and their therapeutic utility
US5561128A (en) * 1989-05-19 1996-10-01 Hoechst-Roussel Pharmaceuticals, Inc. N-[(4-(heteroaryl)-1-piperidinyl)alkyl]-10,11-dihydro-5H-dibenz[B,F]azepines and related compounds and their therapeutic utility
US5658911A (en) * 1989-05-19 1997-08-19 Hoechst Marion Roussel, Inc. Heteroarylpiperidines, and their use as antipsychotics and analgetics
US5801176A (en) * 1995-03-17 1998-09-01 Hoechst Marion Roussel, Inc. Substituted benzothienylpiperazines and their use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411901A (en) * 1981-12-23 1983-10-25 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4452799A (en) * 1981-12-23 1984-06-05 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4656173A (en) * 1985-04-24 1987-04-07 Bristol-Myers Company Antipsychotic benzisothiazole S-oxide compound
GB2181731A (en) * 1985-10-16 1987-04-29 American Home Prod Fused bicyclic imides with psychotropic activity
US4732983A (en) * 1987-04-03 1988-03-22 American Home Products Corporation Pyschotropic polycyclic imides
US4745117A (en) * 1985-03-27 1988-05-17 Sumitomo Pharmaceuticals Company, Limited Imide derivatives and compositions for use as antipsychotic agents
US4797488A (en) * 1987-04-03 1989-01-10 American Home Products Corporation Psychotropic polycyclic imides

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411901A (en) * 1981-12-23 1983-10-25 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4452799A (en) * 1981-12-23 1984-06-05 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4745117A (en) * 1985-03-27 1988-05-17 Sumitomo Pharmaceuticals Company, Limited Imide derivatives and compositions for use as antipsychotic agents
US4656173A (en) * 1985-04-24 1987-04-07 Bristol-Myers Company Antipsychotic benzisothiazole S-oxide compound
GB2181731A (en) * 1985-10-16 1987-04-29 American Home Prod Fused bicyclic imides with psychotropic activity
US4732983A (en) * 1987-04-03 1988-03-22 American Home Products Corporation Pyschotropic polycyclic imides
US4797488A (en) * 1987-04-03 1989-01-10 American Home Products Corporation Psychotropic polycyclic imides

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639764A (en) * 1989-05-19 1997-06-17 Hoechst-Marion-Roussel, Inc. 2-[(4-heteroaryl)-1-piperidinyl)alkyl]-1,3-indandiones and related compound and their therapeutic utility
US5663449A (en) * 1989-05-19 1997-09-02 Hoechst Marion Roussel, Inc. Intermediate compounds in the synthesis of heteroarylpiperidines, pyrrolidines and piperazines
US5554614A (en) * 1989-05-19 1996-09-10 Hoechst-Roussel Pharmaceuticals, Inc. 2-[(4-heteroaryl-1-piperazinyl)alkyl]-1,3-dioxanes and related compounds and their therapeutic utility
US5556858A (en) * 1989-05-19 1996-09-17 Hoechst-Roussel Pharmaceuticals, Inc. Cis-2-[(4-heteroaryl-1-piperazinyl)alkyl] hexahydro-1H-isoindole-1,3 (2H)-diones and related compounds and their therapeutic utility
US5559117A (en) * 1989-05-19 1996-09-24 Hoechst-Roussel Pharmaceuticals, Inc. N-[(4-heteroaryl-1-piperazinyl) alkyl]-2-Benoxazolinines and related compounds and their therapeutic utility
US5559126A (en) * 1989-05-19 1996-09-24 Hoechst-Roussel Pharmaceuticals, Inc. 1-[(1,4-benodioxanyl)alkyl]-4-(heteroaryl)piperidines and related compounds and their therapeutic utility
US5550130A (en) * 1989-05-19 1996-08-27 Hoechst-Roussel Pharmaceuticals, Inc. 1-[(1,4-benzodioxanyl)alkyl]-4-(heteroaryl)piperidines and related compounds and their therapeutic utility
US5561128A (en) * 1989-05-19 1996-10-01 Hoechst-Roussel Pharmaceuticals, Inc. N-[(4-(heteroaryl)-1-piperidinyl)alkyl]-10,11-dihydro-5H-dibenz[B,F]azepines and related compounds and their therapeutic utility
US5569653A (en) * 1989-05-19 1996-10-29 Hoechst-Roussel Pharmaceuticals, Inc. N-[(4-(heteroaryl)-1-pyrrolidinyl)alkyl]-10,11-dihydro-5H-dibenz[B,F]azepines and related compounds and their therapeutic utility
US5648363A (en) * 1989-05-19 1997-07-15 Hoechst Marion Roussel, Inc. N-[(4-heteroaryl-1-piperidinyl)alkyl]-1H-benz[de]isoquinoline-1,3(2H) - diones and related compounds and their therapeutic utility
US5571828A (en) * 1989-05-19 1996-11-05 Hoechst-Roussel Pharmaceuticals, Inc. N-[(3-heteroaryl-1-pyrrolidinyl)alkyl]-2,3-napthalimides and related compounds and their therapeutic utility
US5574032A (en) * 1989-05-19 1996-11-12 Hoechst-Roussel Pharmaceuticals, Inc. N-[(4-(heteroaryl)-1-piperazinyl)alkyl]-10,11-dihydro-5H-dibenz[BFS]azepines and related compounds and their therapeutic utility
US5578624A (en) * 1989-05-19 1996-11-26 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpyrrolidines and their use as antipsychotics and analgesics
US5578605A (en) * 1989-05-19 1996-11-26 Hoechst-Roussel Pharmaceuticals, Inc. N-[(4-heteroaryl)-1-piperidinyl)alkyl]-1,2,3,4-tetrahydroquinolines and related compounds and their therapeutic utility
US5580875A (en) * 1989-05-19 1996-12-03 Hoechst-Roussel Pharmaceuticals, Inc. 1-[(2-pyrimidinyloxy)alkyl]-3-(heteroaryl)pyrrolidines and related compounds and therapeutic utility
US5580890A (en) * 1989-05-19 1996-12-03 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpyrrolidines and their use as antipsychotics and analgesics
US5580886A (en) * 1989-05-19 1996-12-03 Hoechst-Roussel Pharmaceuticals, Inc. Cis-2-[(4-heteroaryl-1-piperidinyl)alkyl]hexahydro-1H-isoindole-1,3(2H)-diones and related compounds and their therapeutic utility
US5580891A (en) * 1989-05-19 1996-12-03 Hoechst-Roussel Pharmaceuticals, Inc. N-[heteroaryl-1-pyrrolidinyl)alkyl]-2-benoxazolinones and related compounds and their therapeutic utility
US5580887A (en) * 1989-05-19 1996-12-03 Hoechst-Roussel Pharmaceuticals, Inc. 1- (arylthioalkyl , arylaminoalkyl or arylmethylenealkyl) -4- (heteroaryl) piperidines and related compounds useful as anti-psychotics and analgesics
US5580879A (en) * 1989-05-19 1996-12-03 Hoechst-Roussel Pharmaceuticals, Inc. N-[(4-heteroaryl-1-pyrrolidinyl)alkyl]-1H-benz[DE]isoquinoline-1;3(2H)-diones and related compounds and their therapeutic utility
US5583145A (en) * 1989-05-19 1996-12-10 Hoechst-Rousell Pharmaceuticals, Inc. 1-(arylthioalkyl, arylaminoalkyl, or arylmethylenealkyl)-4-(heteroaryl)piperazines and related compounds useful as antipsychotics and analgesics
US5589494A (en) * 1989-05-19 1996-12-31 Hoechst-Roussel Pharmaceuticals, Inc. 2-[(3-heteroaryl-1-pyrrolidinyl)alkyl]-1,3-dioxanes and related compounds and their therapeutic utility
US5589488A (en) * 1989-05-19 1996-12-31 Hoechst-Roussel Pharmaceuticals, Inc. N-[(4-heteroaryl-1-piperidinyl)alkyl]-2-benzoxazolinones and related compounds and their therapeutic utility
US5589495A (en) * 1989-05-19 1996-12-31 Hoechst Marion Roussel, Inc. 2-[(3-heteroaryl-1-pyrrolidinyl)alkyl]-1,3- indandiones and related compounds and their therapeutic utility
US5591745A (en) * 1989-05-19 1997-01-07 Hoechst-Roussel Pharmaceuticals, Inc. (4-heteroaryl)-1-[(2,3-dihydro-1H-isoindol-2-yl)alkyl] piperidines and related compounds and their therapeutic utility
US5593995A (en) * 1989-05-19 1997-01-14 Hoechst-Roussel Pharmaceuticals, Inc. 2-[(4-heteroaryl-1-piperazinyl)alkyl]-1,3-indandiones and related compounds and their therapeutic utility
US5597842A (en) * 1989-05-19 1997-01-28 Hoechst-Roussel Pharmaceuticals, Inc. 3-heteroaryl-1-pyrrolidinealkanols and derivatives thereof and their therapeutic utility
US5599821A (en) * 1989-05-19 1997-02-04 Hoechst-Roussel Pharmaceuticals, Inc. 4-heteroaryl-1-piperidinealkylamines and derivatives thereof and their therapeutic utility
US5607945A (en) * 1989-05-19 1997-03-04 Hoechst-Roussel Pharmaceuticals, Inc. N-[(4-(heteroaryl)-1-piperidinyl)alkyl]-1,2,3,4-tetrahydroisoquinolines and related compounds and their therapeutic utility
US5612343A (en) * 1989-05-19 1997-03-18 Hoechst Marion Roussel, Inc. N-[(4-heteroaryl-1-piperazinyl)alkyl]-2,3-naphthalimides and related compounds and their therapeutic utility
US5614543A (en) * 1989-05-19 1997-03-25 Hoechst Marion Roussel, Inc. 1-(aryloxyalkyl)-3- (heteroaryl) pyrrolidines and related compounds useful as antipsychotics and analgesics
US5624927A (en) * 1989-05-19 1997-04-29 Hoechst Marion Roussel, Inc. N-[4-(heteroaryl)-1-piperazinyl)alkyl]-1,2,3,4-tetrahydroisoquinolines and n-[4(heteroaryl)-1-piperazinyl)alkyl]-1,2,3,4-tetrahydroisoquinolines, related compounds and their therapeutic utility
US5629326A (en) * 1989-05-19 1997-05-13 Hoechst-Marion-Roussel, Inc. 4-(heteroaryl)-1-[(2,3-dihydro-1H-indol-1-yl)alkyl]piperidines and related compounds and their therapeutic utility
US5637710A (en) * 1989-05-19 1997-06-10 Hoechst Marion Roussel, Inc. Intermediate compounds in the synthesis of heteroarylpiperidines and piperazines
US5559116A (en) * 1989-05-19 1996-09-24 Hoechst-Roussel Pharmaceuticals, Inc. N-[(4-heteroaryl-1-piperazinyl) alkyl]-1H-benz[de]isoquinoline-1,3 (2H-)-diones and related compounds and their therapeutic utility
US5552414A (en) * 1989-05-19 1996-09-03 Hoechst-Roussel Pharmaceuticals, Inc. 1-(1H-indolyloxyalkyl)-4-(heteroaryl) piperidines and related compounds useful as antipsychotics and analgesics
US5571814A (en) * 1989-05-19 1996-11-05 Hoechst-Roussel Pharmaceuticals, Inc. N-[(4-heteroaryl-1-pyrrolidinyl)alkyl]phthalimides and related compounds and their therapeutic utility
US5652241A (en) * 1989-05-19 1997-07-29 Hoechst Marion Roussel, Inc. 4-(heteroaryl)-1-[(2,3-dihydro-1-indol-1-yl)alkyl]piperadines and related compounds and their therapeutic utility
US5654319A (en) * 1989-05-19 1997-08-05 Hoechst Marion Roussel, Inc. N-[(4-heteroaryl-1-piperidinyl)alkyl]-2,3-naphthalimides and related compounds and their therapeutic utility
US5658911A (en) * 1989-05-19 1997-08-19 Hoechst Marion Roussel, Inc. Heteroarylpiperidines, and their use as antipsychotics and analgetics
US5646161A (en) * 1989-05-19 1997-07-08 Hoechst-Marion-Roussel, Inc. Heteroarylpyrrolidines and their use as antipsychotics and analgesics
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5811430A (en) * 1989-05-19 1998-09-22 Hoechst Marion Roussel, Inc. 1 (2-pyrimidinyloxy) alkyl!-4- (heteroaryl) Piperidines and related compounds and their therapeutic utility
US5811435A (en) * 1989-05-19 1998-09-22 Hoechst Marion Russel, Inc. 2- (4-heteroaryl-1-piperidinyl)alkyl!-1,3-dioxanes and related compounds and their therapeutic utility
US5840727A (en) * 1989-05-19 1998-11-24 Hoechst Marion Roussel Inc (4-heteroaryl)-1- (2,3-dihydro-1H-isoindol-2-yl) alkyl! piperazines and related compounds and their therapeutic utility
US5843977A (en) * 1989-05-19 1998-12-01 Hoechst Marion Rosueel, Inc. (3-heteroaryl-1-pyrrolidinyl) alkoxy!-3,4-dihydro-1(2H)-naphthalenones and related compounds and their therapeutic utility
US5843949A (en) * 1989-05-19 1998-12-01 Hoechst Marion Roussel, Inc. 1-(1H-indolyloxyalkyl)-4-(heteroaryl)piperazines and related compounds useful as antipsychotics and analgesics
US5854263A (en) * 1989-05-19 1998-12-29 Hoechst Marion Roussel, Inc. 1- (1,4-benzodioxanyl)alkyl!-3-(heteroaryl) pyrrolidines and related compounds and their therapeutic utility
US5854243A (en) * 1989-05-19 1998-12-29 Hoechst-Roussel Pharmaceuticals, Inc. 3-heteroaryl-1-pyrrolidinealkylthiols and derivatives thereof and their therapeutic utility
US5874435A (en) * 1989-05-19 1999-02-23 Hoechst Marion Roussel, Inc. 4-heteroaryl-1-piperazinealkanols and derivatives thereof and their therapeutic utility
US5889004A (en) * 1989-05-19 1999-03-30 Hoechst Marion Roussel, Inc. 4-heteroaryl-1-piperazinealkylthiols and derivatives thereof and their therapeutic utility
US5889035A (en) * 1989-05-19 1999-03-30 Hoechst Marion Roussel, Inc. 1-(Arylthioalkyl, arylaminoalkyl or arylmethylenealkyl)-3-(heteroaryl) pyrrolidines and related compounds useful as antipsychotics and analgesics
US5919798A (en) * 1989-05-19 1999-07-06 Hoechst Marion Roussel, Inc. 4-heteroaryl-1-piperidinealkanols and derivatives thereof and their therapeutic utility
US5965546A (en) * 1989-05-19 1999-10-12 Hoechst Marion Roussel, Inc. 1-[(2-pyrimidinyloxy)alkyl]4-(heteroaryl)piperazines and related compounds and their therapeutic utility
US5977113A (en) * 1989-05-19 1999-11-02 Hoechst Marion Roussel, Inc. 4-heteroaryl-1-piperazine alkylamines and their therapeutic utility
US5977140A (en) * 1989-05-19 1999-11-02 Hoechst Marion Roussel, Inc. N-[(4-Heteroaryl-1-Piperidinyl)Alkly] Phthalimides and related compounds and their therapeutic utility
US5998417A (en) * 1989-05-19 1999-12-07 Hoechst Marion Roussel, Inc. N-[(4-heteroaryl-1-piperazinyl) alkyl]phthalimides and related compounds and their therapeutic utility
US6001834A (en) * 1989-05-19 1999-12-14 Hoechst-Roussel Pharmaceuticals, Inc. [(4-heteroaryl-1-piperazinyl)alkoxy]-3,4-dihydro-1(2h)-naphthalenones and related compounds and their therapeutic utility
US6043240A (en) * 1989-05-19 2000-03-28 Hoechst Marion Roussel, Inc. 3-heteroaryl-1-pyrrolidinealkylamines and derivatives thereof and their therapeutic utility
US6110938A (en) * 1989-05-19 2000-08-29 Hoescht Marion Roussel, Inc. 1-(arylthioalkyl, arylaminoalkyl or arylmethylenealkyl)-4-(heteroaryl)piperidines and related compounds useful as antipsychotics and analgesics
US6140345A (en) * 1989-05-19 2000-10-31 Aventis Pharmaceuticals Inc. 1-(aryloxyalkyl)-4-(heteroaryl)piperidines and related compounds useful as antipsychotics and analgesics
USRE37029E1 (en) * 1989-05-19 2001-01-23 Aventis Pharmaceuticals Inc. N-[(3-heteroaryl-1-pyrrolidinyl)-alkyl]phthalimides and related compounds and their therapeutic utility
USRE37478E1 (en) 1989-05-19 2001-12-18 Aventis Pharmaceuticals, Inc. 1-(arylthioalkyl, arylaminoalkyl, or arylmethylenealkyl)-4-(heteroaryl)piperazines and related compounds useful as antipsychotics and analgesics
USRE37729E1 (en) 1989-05-19 2002-06-04 Aventis Pharmaceuticals Inc. 4-Heteroaryl-1-piperidinealkylamines and derivatives thereof and their therapeutic utility
USRE39265E1 (en) 1989-05-19 2006-09-05 Aventis Pharmaceuticals Inc. Heteroarylpiperidines, and their use as antipsychotics and analgetics
USRE39198E1 (en) 1989-05-19 2006-07-18 Aventis Pharmaceuticals Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics
WO1993016073A1 (en) * 1992-02-12 1993-08-19 The Wellcome Foundation Limited Piperazine and piperidine derivatives, and their use as antipsychotics
US6420390B1 (en) 1993-10-28 2002-07-16 Aventis Pharmaceuticals Inc. Heteroarylpiperidines and their use as antipsychotics
US6251907B1 (en) 1993-10-28 2001-06-26 Aventis Pharmaceuticals Inc. 1-(aryloxyalkyl)-4-(heteroaryl) piperazines and related compounds useful as antipsychotics and analgesics
US5801176A (en) * 1995-03-17 1998-09-01 Hoechst Marion Roussel, Inc. Substituted benzothienylpiperazines and their use

Similar Documents

Publication Publication Date Title
US4797406A (en) Amides and esters containing bridged piperidines and use as serotonin M antagonists
US4797488A (en) Psychotropic polycyclic imides
US4873331A (en) Noradamantyl-carboxylic acid piperazinoalkyl esters
EP0125607A2 (en) Pyrido(1,5)benzodiazepinone derivatives and pharmacological activities thereof
US4748240A (en) Psychotropic bicyclic imides
WO1992020681A1 (en) Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
US6057321A (en) 1,4-diazabicyclo [2.2.2] oct-2-ylmethyl derivatives, their preparation and therapeutic application
FI112866B (en) Process for the preparation of novel therapeutically useful amide derivatives of hexahydro-8-hydroxy-2,6-methano-2H-quinolizines and intermediates used in the process
KR860001252B1 (en) Process for preparing 9-(3-(3,5-cis-dimethyl-piperazino)propyl) carbazole
US4968792A (en) Psychotropic benzisothiazole derivatives
US5955470A (en) Derivatives of amide analogs of certain methano bridged quinolizines
US4910302A (en) Psychotropic polycyclic imides
EP0749971B1 (en) Thiopyran derivatives
US4591589A (en) 2-aryl pyrazolo[4,3-c]cinnolin-3-ones
US4634708A (en) Indolophenanthridines useful as dopaminergic and analgesic agents
DE69514315T2 (en) AZABICYCLOALKYL DERIVATIVES FROM IMIDAZO [1,5-a] INDOL-3-ONE AS 5HT3 ANTAGONISTS
US4778812A (en) 2,3-dihydro-9-methyl-1H-pyrrolo[1,2-a]indol-1-amines and derivatives thereof
HUT71132A (en) Bis-aryl-carbinol derivatives, pharmaceutical compositions containing them and process for producing
US4798896A (en) Antipsychotic gamma-carboline N-oxides
WO1999038864A1 (en) Oxazole derivatives as serotonin-1a receptor agonists
US4824999A (en) Psychotropic polycyclic imides
US4732983A (en) Pyschotropic polycyclic imides
US4983603A (en) Tricyclic cholinergic receptor agonists
US6057340A (en) Oxazole derivatives as serotonin-1A receptor agonists
KR900005034B1 (en) Fused Bicyclic Imide and Method for Making the Same

Legal Events

Date Code Title Description
AS Assignment

Owner name: AMERICAN HOME PRODUCTS CORPORATION, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:STACK, GARY P.;ABOU-GHARBIA, MAGID ABDEL-MEGID;GOLOBISH, THOMAS D.;REEL/FRAME:005153/0469;SIGNING DATES FROM 19890914 TO 19890922

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: WYETH, NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:AMERICAN HOME PRODUCTS CORPORATION;REEL/FRAME:012822/0248

Effective date: 20020311

REMI Maintenance fee reminder mailed